Jan 08, 2024 / 04:15PM GMT
Arvind Ramaiah JP Morgan Chase&CO.-Analyst
And now welcome to the first day of the 42nd Annual JPMorgan Healthcare Conference. My name is Arvind Ramaiah, I'm an associate with the New York City investor -- Healthcare Investment Banking Group at JP Morgan. And it is my absolute pleasure today to introduce Chris Anzalone, President and CEO of Arrowhead Pharmaceuticals.
Christopher Anzalone Arrowhead Pharmaceuticals - Inc. - CEO, President
And so it begins. Thanks very much for having us, it's really great pleasure to be here. So I was just talking earlier, generally these -- generally I do fireside chats and these sorts of things, and I find that those are helpful. And so I've got only 12 or 13 slides and I'll run through them. Hopefully rather quickly, so we can get to questions and answers. I think it's more productive with us to proceed. All right, this will be the first of 1,000 of statements DLC. You'll see Please refer to our filings before making investment decisions.
Okay. So we are as of Friday, which we closed at $35
Arrowhead Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
